Navigation Links
Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
Date:11/1/2012

TITUSVILLE, N.J., Nov. 1, 2012 /PRNewswire/ -- Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV). The regimen will include Janssen's investigational protease inhibitor simeprevir (TMC435) and Vertex's investigational nucleotide analogue HCV polymerase inhibitor VX-135. As a first step, Janssen will conduct a drug-drug interaction (DDI) study with simeprevir and VX-135. The DDI study will support the initiation of the Phase 2 study in early 2013 pending discussions with regulatory authorities.

The goal of the Phase 2 study will be to evaluate the safety, tolerability and viral cure rates of a 12-week regimen of simeprevir and VX-135, administered with and without ribavirin, in treatment-naive patients who have chronic non-cirrhotic genotype 1 HCV. The companies will jointly fund development costs associated with the collaboration. There are no up-front or milestone payments associated with the agreement.

Simeprevir is an investigational NS3/4A protease inhibitor currently in Phase 3 trials, developed in collaboration with and licensed from Medivir AB. VX-135 is an investigational uridine nucleotide analogue pro-drug designed to inhibit the replication of HCV by acting on the NS5B polymerase. 

"There is a significant unmet need for all-oral treatment regimens for people living with hepatitis C," said Wim Parys, Global Head of Infectious Diseases at Janssen. "Janssen's collaboration with Vertex underscores our commitment to better understand the potential utility of simeprevir in a number of different interferon-free treatment combinations and HCV patient populations."

About Simeprevir
Simeprevir (TMC435) is an NS3/4A protease inhibitor jointly developed by Janssen and Medivir AB to treat chronic HCV infection. Simepr
'/>"/>

SOURCE Janssen Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
2. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
4. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
5. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
6. Anthera Announces the Phase 2b PEARL-SC Data Has Been Accepted as a Late Breaking Poster Presentation at the ACR/ARHP 2012 Annual Scientific Meeting
7. Watson Announces Global Generics Management Team
8. Watson Announces New Name -- Actavis -- for Global Operations
9. BioMed Realty Announces 93,000 Square Foot Lease Expansion And Extension With Ironwood Pharmaceuticals At 301 Binney Street
10. Abaxis Announces Exclusive Distribution Agreement with Abbott
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... -- Research and Markets has announced the addition ... Diarrhea, Mental Disorder) Market - Forecast to 2023" report ... report, the human microbiome market is segmented by application, disease, ... expected to be valued as $294 million in 2019 and ... the forecast period of 2019-2023. The market is driven by ...
(Date:9/19/2014)... 2014 Five MinuteClinic walk-in medical clinics are opening inside ... area. Three clinics opened in Memphis and ... will be added in Springfield on September ... is expected to open October 22.  MinuteClinic is the largest and ... United States . The Memphis ...
(Date:9/19/2014)... SAN DIEGO , Sept. 19, 2014 /PRNewswire/ ... industry leader in bioactive lipid-targeted therapeutics, announced today ... sell 3,605,042 registered shares of common stock and ... The combined purchase price for one registered share ... purchase one unregistered share of common stock will ...
Breaking Medicine Technology:Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3MinuteClinic Walk-in Medical Clinics Opening in Memphis 2MinuteClinic Walk-in Medical Clinics Opening in Memphis 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3
... American Scientific Resources, Incorporated (OTCQB: ASFX) today ... S.E.C. containing results for the quarter ending March ... to review the entire 10-Q filing. ... would also like to direct investors to its ...
... 2011 The National Community Pharmacists Association ... Schock (R-Ill.) and Peter Welch (D-Vt.) ... testing supplies, and expert counseling on their proper use, ... http://photos.prnewswire.com/prnh/20100106/DC33253LOGO ) "We commend Reps. Schock ...
Cached Medicine Technology:American Scientific Resources, Inc. Announces Quarterly Results 2NCPA Urges Congress to Preserve Seniors' Access to Diabetes Supplies at Independent Community Pharmacies; Back Schock-Welch Bill 2
(Date:9/21/2014)... Dallas, Texas (PRWEB) September 22, 2014 ... over the past decade, as it has become ... short-acting beta-agonists (SABAs), inhaled corticosteroids (ICSs), inhaled corticosteroids ... has also been facing increasing generic competition. However, ... and once-daily ICS and ICS/LABA therapies delivered by ...
(Date:9/21/2014)... 21, 2014 "I want to help ... back but haven’t the money for chiropractors," said an ... have such a product for myself." , The Stretch ... stretch the thigh muscles and align the spine properly. ... relieves discomfort of pinched nerves. Compact and easy to ...
(Date:9/21/2014)... women starting college understand the benefits of a healthy ... they aren,t confident they can follow through on these ... The study involved 268 female college freshmen enrolled ... Eating Right program. The students answered food-related questions such ... were very busy with school work, were very hungry ...
(Date:9/21/2014)... (PRWEB) September 21, 2014 Originally ... in 1996, GSK’s Flovent (fluticasone propionate) is a ... is used for the maintenance treatment of asthma ... available in two formulations, Diskus and HFA, which ... respectively. Flovent’s active ingredient, fluticasone propionate, can bind ...
(Date:9/21/2014)... 21, 2014 High in the rugged ... disabled and able-bodied athletes rafted the Colorado River, rode ... course in pursuit of outdoor adventure. At the September ... World T.E.A.M. Sports, disabilities proved to be no more ... the three stage event. , Each participating team of ...
Breaking Medicine News(10 mins):Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Spiriva Asthma Market (Tiotropium Bromide) Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News: College Women Can Use Food Strategies, Study Finds 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 2Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 3Health News:Flovent Asthma Market Sales & SWOT Analysis and Forecasts to 2023 in New Report Available at LifeScienceIndustryResearch.com 4Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 2Health News:Disabled Athletes Excel at World T.E.A.M. Sports’ Adventure Team Challenge 3
... in Federal Funds Awarded to Reconstruct Devastating,Injuries;, ... HEIGHTS, Ill., April 17 Members of,the American ... pivotal role,over the next five years developing groundbreaking ... Iraq and Afghanistan. The U.S.,Department of Defense (DoD) ...
... for cosmetic purposes might also improve wound healing and ... scarred during combat. Dr. Adam Katz, plastic surgeon and ... conduct research in this area under the Armed Forces ... announce the formation of AFIRM, which has received more ...
... CARLSBAD, Calif., April 17 The National Center ... resource for autism research, education and family support,services ... Families are,flocking to NCARE resulting from the announcement ... is that families desperately need centralized,autism resources., ...
... With Information and,Best Practices Related to Upcoming ... April 17 The new Centers for,Medicare ... eliminate or,reduce payments for three hospital-acquired infections ... conference for healthcare executives and professionals,sponsored by ...
... The National,Association of Specialty Health Organizations ... Innovation Award. The recipient of the award,will ... through,innovative programs and practices., (Logo: ... for the specialty health industry, we felt ...
... April 17 MSA (NYSE: MSA ), the,global ... that protect people,s health and safety, announced today that ... live via the,Internet on Thursday, May 1, 2008 at ... Investors and interested parties will have the opportunity ...
Cached Medicine News:Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 2Health News:Plastic Surgeons Play Pivotal Role in War Injury Research 3Health News:UVA Health System part of Armed Forces multi-million dollar effort to help soldiers 2Health News:California's First Non-profit Center for Autism Research, Education and Family Services 2Health News:APIC Conference to Address New CMS Regulations 2Health News:The National Association of Specialty Health Organizations to Recognize Excellence in Technology Education With Industry Award 2Health News:MSA Schedules First Quarter Earnings Webcast 2
Optimal solution for normal acetabulum....
The Biopro All Poly cup is a uniquely designed UHMWPE acetabular cup....
The Pe-Plus offers an additional clinical option for replacing the acetabulum....
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
Medicine Products: